Leading global law firm Herbert Smith Freehills Kramer has advised on Medcaptain Medical Technology Co., Ltd. (02041.HK)’s listing on the Main Board of the Hong Kong Stock Exchange.
Medcaptain is a global medical device provider supplying medical institutions, community health centres, testing facilities and homecare providers in China and over 140 other countries globally. The company’s product portfolio includes life support products, minimally invasive intervention products and in-vitro diagnostic products.
Medcaptain’s innovative and high-quality medical products, along with its extensive coverage across clinical departments, position it as one of the most comprehensive medical device companies in China. Its products have cumulatively reached over 6,000 hospitals in China, including approximately 90% of Grade 3A hospitals, covering 31 provinces, municipalities and autonomous regions.
“Hong Kong continues to provide opportunities for companies seeking to access international capital markets,” said Hong Kong partner Matt Emsley. “Investors are focused on quality and execution, and Medcaptain’s listing reflects Hong Kong’s continued relevance as a venue for specialist healthcare issuers.”
Herbert Smith Freehills Kramer has a strong track record advising healthcare and pharmaceutical companies on Hong Kong listings. Over the past eight years, the firm has advised on more than 30 healthcare and pharmaceutical IPOs in Hong Kong.
“We congratulate Medcaptain on its successful listing on the Hong Kong Stock Exchange,” said Beijing partner Stanley Xie. “This is an important milestone for the company as it enters the public markets, and we are pleased to have supported Medcaptain with our experience across cross-border capital markets and the healthcare sector.”
Partners Matt Emsley, Stanley Xie and Jin Kong* led a cross-office team advising the client, assisted by Jaime Fong, Scarlet Feng, Cyrus Wong, Samuel Au, Vera Chen, Francis Wang, Renee Fung, Maxine Law and Huaien Tang.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.